AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17854523 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist administration (group B)
Number of subjects: 190
Study 17854523 — intervention group
Group type: COMPARATOR
Intervention: Coasting (group A)
Number of subjects: 190
Study 17854523 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 190
Study 15129927 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1000 mg calcium citrate/400 I.U. Vitamin D)
Number of subjects: 48
Study 15129927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 11304901 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (37.5 mg bid for 7 days, then 75 mg bid until Day 28)
Number of subjects: 28
Study 11304901 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (20 mg daily for 28 days)
Number of subjects: 28
Study 9345339 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF 80 micrograms/m2/day as 2-h infusion on days 1-5 + IL-2 1 x 10(6) IU/m2/day continuous infusion on days 1-5 for 3 weeks + IFN-alpha 9 x 10(6) IU/m2/day s.c. or i.m. on days 1, 3, and 5 for 3 weeks
Number of subjects: 18
Study 9345339 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF 40 micrograms/m2/day as a 2-h infusion on days 1-5 + IL-2 3 x 10(6) IU/m2/day continuous infusion on days 1-5 for 3 weeks + IFN-alpha 9 x 10(6) IU/m2/day s.c. or i.m. on days 1, 3, and 5 for 3 weeks
Number of subjects: 18
Study 9345339 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of TNF, IL-2, and IFN-alpha
Number of subjects: 18
Study 8093745 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of metabolic acidosis markers (base deficit in blood and extracellular fluid, bicarbonate concentration)
Number of subjects: 20
Study 8093745 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood base deficit of -4.65 or less
Number of subjects: 20
Study 8093745 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracellular-fluid base deficit of -6.13 or less
Number of subjects: 20
Study 8093745 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine blood-gas measurements
Number of subjects: 20
Study 3481160 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 1.0 mM CuSO4 and 2.0 mM hexetidine
Number of subjects: 7
Study 3481160 — intervention group
Group type: COMPARATOR
Intervention: 1.0 mM CuSO4
Number of subjects: 7
Study 3481160 — intervention group
Group type: COMPARATOR
Intervention: 2.0 mM hexetidine
Number of subjects: 7
Study 3481160 — intervention group
Group type: COMPARATOR
Intervention: H2O
Number of subjects: 7
Study 3481160 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexetidine
Number of subjects: 7
Study 29957750 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticort plus®
Number of subjects: 80
Study 29957750 — intervention group
Group type: COMPARATOR
Intervention: Seretide®
Number of subjects: 80
Study 29957750 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticort plus® and Seretide®
Number of subjects: 80
Study 27742728 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 14671
Study 27742728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14671
Study 26537500 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised pharmacy student-led medication review
Number of subjects: 133
Study 26537500 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 133
Study 24097128 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg three times daily
Number of subjects: 416
Study 24097128 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin‐clavulanic acid 500 mg/125 mg three times daily
Number of subjects: 416
Study 24097128 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 416
Study 20381077 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (n = 40), continuous infusion at a rate of 0.73 mg/min for 96 hours (total dose 4200 mg)
Number of subjects: 80
Study 20381077 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 40), no prophylaxis
Number of subjects: 80
Study 20381077 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (n = 40)
Number of subjects: 80
Study 20381077 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 40)
Number of subjects: 80
Study 17716953 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention combining behavioral counseling and nicotine replacement (open-label)
Number of subjects: 0
Study 17716953 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain prevention lifestyle intervention
Number of subjects: 0
Study 17716953 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure control lifestyle intervention
Number of subjects: 0
Study 17716953 — intervention group
Group type: COMPARATOR
Intervention: Usual lifestyle intervention
Number of subjects: 0
Study 17160761 — intervention group
Group type: EXPERIMENTAL
Intervention: Plexiglas hysterosalpingographic vacuum cup
Number of subjects: 226
Study 17160761 — intervention group
Group type: COMPARATOR
Intervention: Standard two-way catheter
Number of subjects: 226
Study 12823075 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose risperidone (starting dose of 0.25 mg/day, titrated upward to 2 mg/day)
Number of subjects: 25
Study 12823075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 10859225 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide 30 microg (tid, sc)
Number of subjects: 0
Study 10859225 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide 60 microg (tid, sc)
Number of subjects: 0
Study 10859225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10859225 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide (30 and 60 microg)
Number of subjects: 0
Study 8860007 — intervention group
Group type: EXPERIMENTAL
Intervention: G6PD deficiency subjects (n=18)
Number of subjects: 166
Study 8860007 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrophoresis on 166 samples
Number of subjects: 166
Study 8860007 — intervention group
Group type: EXPERIMENTAL
Intervention: G6PD deficient subjects (n=18)
Number of subjects: 166
Study 8860007 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotyping of G6PD deficient subjects (n=18)
Number of subjects: 166
Study 1514347 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose intramuscular ketamine (1 mg/kg)
Number of subjects: 30
Study 1514347 — intervention group
Group type: COMPARATOR
Intervention: Pethidine (1 mg/kg)
Number of subjects: 30
Study 6088248 — intervention group
Group type: EXPERIMENTAL
Intervention: CCNU, cyclophosphamide, vincristine and methotrexate (CCOM) with consolidation locoregional radiation (30 Gy) after two courses of chemotherapy for LD patients.
Number of subjects: 57
Study 6088248 — intervention group
Group type: COMPARATOR
Intervention: Maintenance chemotherapy after consolidation radiotherapy for a subset of 12 LD patients achieving CR.
Number of subjects: 57
Study 31058762 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning exercise (AM)
Number of subjects: 16
Study 31058762 — intervention group
Group type: EXPERIMENTAL
Intervention: Afternoon exercise (PM)
Number of subjects: 16
Study 31058762 — intervention group
Group type: COMPARATOR
Intervention: Control condition (rested)
Number of subjects: 16
Study 29890368 — intervention group
Group type: EXPERIMENTAL
Intervention: Light Virtual Reality training program
Number of subjects: 60
Study 29890368 — intervention group
Group type: COMPARATOR
Intervention: User manual
Number of subjects: 60
Study 29890368 — intervention group
Group type: COMPARATOR
Intervention: Fixed-base simulator
Number of subjects: 60
Study 27251974 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD + ABG (combination group)
Number of subjects: 12
Study 27251974 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD alone (EMD group)
Number of subjects: 12
Study 27251974 — intervention group
Group type: COMPARATOR
Intervention: OFD (control group)
Number of subjects: 12
Study 24344912 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek LS Low Shrink Posterior Restorative
Number of subjects: 31
Study 24344912 — intervention group
Group type: COMPARATOR
Intervention: Tetric EvoCeram
Number of subjects: 31
Study 23387216 — intervention group
Group type: EXPERIMENTAL
Intervention: HX0507 (3 mg/kg and 8 mg/kg or above)
Number of subjects: 80
Study 21053621 — intervention group
Group type: EXPERIMENTAL
Intervention: Yinian Jiangya Yin
Number of subjects: 79
Study 21053621 — intervention group
Group type: COMPARATOR
Intervention: Tianma Gouteng Yin
Number of subjects: 79
Study 17175564 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (dose-adjusted, INR 2.0-3.0)
Number of subjects: 75
Study 17175564 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (300 mg)
Number of subjects: 75
Study 15838335 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin (800 mug)
Number of subjects: 5
Study 15838335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 11853280 — intervention group
Group type: EXPERIMENTAL
Intervention: Menatetrenone-4 plus elemental calcium carbonate 800 mg/day
Number of subjects: 83
Study 11853280 — intervention group
Group type: COMPARATOR
Intervention: Elemental calcium carbonate 800 mg/day
Number of subjects: 83
Study 9596112 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-761 (200 mg orally, 5 h prior to exercise)
Number of subjects: 10
Study 9596112 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matched placebo, 5 h prior to exercise)
Number of subjects: 10
Study 9596112 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-761
Number of subjects: 10
Study 7816491 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid group (group S, n = 14) received 0.5% lidocaine plus triamcinolone acetonide (10 mg/ml).
Number of subjects: 24
Study 7816491 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid plus morphine group (group S + M, n = 10) received the same combination plus 2.5 mg of morphine sulphate.
Number of subjects: 24
Study 3354495 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular administration of retinyl palmitate (100,000 IU, or 30 mg retinol equivalent)
Number of subjects: 30
Study 3354495 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A injections
Number of subjects: 30
Study 31464511 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-Release and Extended-Release Methylphenidate (DR/ER-MPH)
Number of subjects: 117
Study 31464511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 30005809 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured peer-feedback (PF)
Number of subjects: 59
Study 30005809 — intervention group
Group type: COMPARATOR
Intervention: Faculty-feedback (FF)
Number of subjects: 59
Study 28483685 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-load exercise of shoulder muscles
Number of subjects: 90
Study 28483685 — intervention group
Group type: COMPARATOR
Intervention: Inactive ultrasound for 10 minutes (placebo)
Number of subjects: 90
Study 28483685 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 90
Study 28483685 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including low-load exercise)
Number of subjects: 90
Study 25992985 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-ligating brackets
Number of subjects: 16
Study 25992985 — intervention group
Group type: COMPARATOR
Intervention: Conventional brackets
Number of subjects: 16
Study 23742659 — intervention group
Group type: EXPERIMENTAL
Intervention: High Protein (HP) yogurt (14.0 g protein)
Number of subjects: 32
Study 23742659 — intervention group
Group type: COMPARATOR
Intervention: Normal Protein (NP) yogurt (5.0 g protein)
Number of subjects: 32
Study 23742659 — intervention group
Group type: EXPERIMENTAL
Intervention: HP yogurt
Number of subjects: 32
Study 23742659 — intervention group
Group type: COMPARATOR
Intervention: NP yogurt
Number of subjects: 32
Study 23742659 — intervention group
Group type: EXPERIMENTAL
Intervention: HP yogurt and NP yogurt
Number of subjects: 32
Study 21339275 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 200
Study 21339275 — intervention group
Group type: COMPARATOR
Intervention: Cephalexin
Number of subjects: 200
Study 19376240 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose endotoxin
Number of subjects: 0
Study 19376240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19376240 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose endotoxin (females)
Number of subjects: 0
Study 19376240 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose endotoxin (males)
Number of subjects: 0
Study 15848571 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SL) 3 mg/d for African Americans; 2 mg/d for others, starting on days 2 and 3, adjusted to 8 to 10 ng/d by weeks 3 to 4 posttransplant.
Number of subjects: 152
Study 15848571 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC) levels 15 to 20 ng/mL, progressively reduced to 5 ng/mL by 3 months.
Number of subjects: 152
Study 15848571 — intervention group
Group type: COMPARATOR
Intervention: Basiliximab (BX) induction, TAC, and steroids without SL (Group 2).
Number of subjects: 152
Study 11915062 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2%
Number of subjects: 60
Study 11915062 — intervention group
Group type: EXPERIMENTAL
Intervention: Levo-bupivacaine 0.25%
Number of subjects: 60
Study 11915062 — intervention group
Group type: COMPARATOR
Intervention: Racemic bupivacaine 0.25%
Number of subjects: 60
Study 9620309 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB radiation
Number of subjects: 0
Study 7621742 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative irradiation with 10 Gy in 5 fractions
Number of subjects: 216
Study 7621742 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative irradiation with 7 Gy in one fraction
Number of subjects: 216
Study 7621742 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative irradiation during the first 4 postoperative days
Number of subjects: 216
Study 7621742 — intervention group
Group type: COMPARATOR
Intervention: No irradiation (control group)
Number of subjects: 216
Study 2201413 — intervention group
Group type: EXPERIMENTAL
Intervention: Myrcia uniflora
Number of subjects: 54
Study 2201413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 2201413 — intervention group
Group type: EXPERIMENTAL
Intervention: Bauhinia forficata
Number of subjects: 54
Study 343995 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% hydrocortisone plus 10% urea ('Alphaderm')
Number of subjects: 21
Study 343995 — intervention group
Group type: COMPARATOR
Intervention: 0.1% betamethasone 17-valerate
Number of subjects: 21
Study 30528227 — intervention group
Group type: EXPERIMENTAL
Intervention: rhHNS IT 45 mg administered every 2 weeks (Q2W)
Number of subjects: 21
Study 30528227 — intervention group
Group type: EXPERIMENTAL
Intervention: rhHNS IT 45 mg administered every 4 weeks (Q4W)
Number of subjects: 21
Study 30528227 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 21
Study 29051306 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermoneutral head out water immersion (HOWI)
Number of subjects: 0
Study 25830421 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-lactam monotherapy
Number of subjects: 2283
Study 25830421 — intervention group
Group type: COMPARATOR
Intervention: Beta-lactam-macrolide combination therapy
Number of subjects: 2283
Study 25830421 — intervention group
Group type: COMPARATOR
Intervention: Fluoroquinolone monotherapy
Number of subjects: 2283
Study 23850227 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol infusion (4 mg)
Number of subjects: 16
Study 23850227 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 16
Study 21463520 — intervention group
Group type: EXPERIMENTAL
Intervention: intensive treatment plus the facilitator‐led individual behaviour change intervention (n = 239)
Number of subjects: 478
Study 21463520 — intervention group
Group type: COMPARATOR
Intervention: intensive treatment alone (n = 239)
Number of subjects: 478
Study 19826393 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) 2.5 mg injections at 4-week intervals
Number of subjects: 26
Study 19826393 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure (subconjunctival normal saline)
Number of subjects: 26
Study 19826393 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (IVB and control)
Number of subjects: 26
Study 16478882 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVPP (doxorubicin, bleomycin, vinblastine, procarbazine, prednisone)
Number of subjects: 533
Study 16478882 — intervention group
Group type: COMPARATOR
Intervention: MOPP/ABV (mechlorethamine, vincristine, procarbazine, prednisone/Adriamycin [doxorubicin], bleomycin, vinblastine)
Number of subjects: 533
Study 16478882 — intervention group
Group type: COMPARATOR
Intervention: MOPP/ABV with RT (subtotal nodal irradiation)
Number of subjects: 533
Study 16478882 — intervention group
Group type: COMPARATOR
Intervention: ABVPP with RT (subtotal nodal irradiation)
Number of subjects: 533
Study 16478882 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation CT (chemotherapy)
Number of subjects: 533
Study 16478882 — intervention group
Group type: EXPERIMENTAL
Intervention: RT (subtotal nodal irradiation)
Number of subjects: 533
Study 14739801 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid administration (7 ml/kg hydroxyethyl starch)
Number of subjects: 12
Study 14739801 — intervention group
Group type: COMPARATOR
Intervention: Vasopressor (0.2 mg/kg ephedrine)
Number of subjects: 12
Study 14739801 — intervention group
Group type: COMPARATOR
Intervention: Epidural anesthesia
Number of subjects: 12
Study 11282812 — intervention group
Group type: EXPERIMENTAL
Intervention: External self-exposure treatment
Number of subjects: 80
Study 11282812 — intervention group
Group type: EXPERIMENTAL
Intervention: Interoceptive self-exposure treatment
Number of subjects: 80
Study 11282812 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined external and interoceptive self-exposure treatment
Number of subjects: 80
Study 11282812 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 9093301 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of five-valent pneumococcal conjugate vaccine (PCV)
Number of subjects: 51
Study 9093301 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 51
Study 7653738 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical levocabastine (eye-drops and nasal spray)
Number of subjects: 95
Study 7653738 — intervention group
Group type: COMPARATOR
Intervention: Oral loratadine
Number of subjects: 95
Study 3150824 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of luteinizing hormone‐releasing analogue (GnRHa, Buserelin) and pulsatile administration of hMG (Group I)
Number of subjects: 9
Study 3150824 — intervention group
Group type: COMPARATOR
Intervention: Pulsatile hMG administration alone (Group II)
Number of subjects: 9
Study 28816509 — intervention group
Group type: EXPERIMENTAL
Intervention: SHP465 mixed amphetamine salts (MAS) 12.5-25 mg
Number of subjects: 264
Study 28816509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study 28816509 — intervention group
Group type: EXPERIMENTAL
Intervention: SHP465 mixed amphetamine salts (MAS)
Number of subjects: 264
Study 27443485 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard quitline plus weight management program (simultaneously)
Number of subjects: 2550
Study 27443485 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard quitline plus weight management program (sequentially)
Number of subjects: 2550
Study 27443485 — intervention group
Group type: COMPARATOR
Intervention: Standard quitline
Number of subjects: 2550
Study 23774079 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered lidocaine
Number of subjects: 52
Study 23774079 — intervention group
Group type: COMPARATOR
Intervention: Unbuffered lidocaine
Number of subjects: 52
Study 23477890 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine (500 mg IV four times per week)
Number of subjects: 243
Study 23477890 — intervention group
Group type: COMPARATOR
Intervention: No Amifostine
Number of subjects: 243
Study 20801495 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine
Number of subjects: 6505
Study 20801495 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 6505
Study 18158380 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Deprivation (SD) therapy (six nights of total SD, separated by recovery sleep)
Number of subjects: 19
Study 18158380 — intervention group
Group type: COMPARATOR
Intervention: No Sleep Deprivation therapy (Control group)
Number of subjects: 19
Study 16419700 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming needle moxibustion
Number of subjects: 90
Study 16419700 — intervention group
Group type: COMPARATOR
Intervention: Nimeisulide (oral administration)
Number of subjects: 90
Study 16419700 — intervention group
Group type: COMPARATOR
Intervention: 654-2 (injection)
Number of subjects: 90
Study 12074345 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated stents
Number of subjects: 40
Study 12074345 — intervention group
Group type: COMPARATOR
Intervention: Uncoated Palmaz-Schatz stents
Number of subjects: 40
Study 10405080 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimensional representations of psychotic psychopathology
Number of subjects: 706
Study 10405080 — intervention group
Group type: COMPARATOR
Intervention: Categorical representations of psychotic psychopathology
Number of subjects: 706
Study 7748214 — intervention group
Group type: EXPERIMENTAL
Intervention: Every-other-week methotrexate (MTX)
Number of subjects: 47
Study 7748214 — intervention group
Group type: COMPARATOR
Intervention: Weekly methotrexate (MTX)
Number of subjects: 47
Study 2178379 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 2466
Study 2178379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2466
Study 36066 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound A (Actified)
Number of subjects: 14
Study 36066 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 14
Study 36066 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound B (Dristan)
Number of subjects: 14
Study 36066 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall performance (MTPB)
Number of subjects: 14